menu
    • menu

    Company profile for Famar

    Famar-PSE
    News
    Famar Acquires Sterile Manufacturing Site in Homburg, Germany

    15 May 2025

    // PRESS RELEASE

    FAMAR achieves EcoVadis Gold

    02 Apr 2025

    // PRESS RELEASE

    FAMAR Appoints New Executive to Leadership Team

    06 Jan 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Famar

    Contact Supplier

    Website

    CPhI North America

    Not Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.pharmacompass.com/video-supplier-spotlight/famar/famar-heritage

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    FAMAR CDMO- From early development to commercial manufacturing.

    Related CompaniesRelated Companies

    About

    FAMAR is a leading European contract manufacturing and development organization serving the pharmaceutical industry. The company has more than 75 years track record of delivering quality and value to customers across all finished dosage forms including sterile liquids, solids, and semi-solids.
    FAMAR has a workforce of 1,850 employees across a network of six manufacturing sites and two R&D centres in Spain, Italy, and Greece. FAMAR currently supplies 1.700 different products to more than 80 international markets.

    Learn more about Famar: http://www.famar-group.com

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    FamarGreece Flag
    Country
    Country
    Greece
    Address
    Address
    Agiou Dimitriou 63, 17456, Alimos, Athens
    Telephone
    Telephone
    +30 2109898500
    Client Email
    Email
    m.rotas@famar-group.com
    Client Website
    Website
    https://famar-group.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/famar/
    youtube
    YouTube
    http://www.youtube.com/@famar-group
    Twitter
    Twitter
    Contact Info
    Others

    “Ready-to-use” Solutions & Services:

     https://compassbyfamar.com/

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Attending

    envelop Contact Supplier

    CPhI North America

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-96278.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Leadership Awards 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-25120.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    COMPASS: New Services Business Unit

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-49662.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Regulatory Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-79304.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Product Compliance Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-70471.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    R&D Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-9343.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Pilot Plant

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-71783.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/famar-party-content-45381.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3080

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3752

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Famar Acquires Sterile Manufacturing Site in Homburg, Germany
    Famar Acquires Sterile Manufacturing Site in Homburg, Germany

    15 May 2025

    // PRESS RELEASE

    https://www.famar-group.com/new/famar-group-announces-acquisition-of-sterile-manufacturing-site-in-homburg-germany/

    PRESS RELEASE
    15 May 2025
    Share Share
    FAMAR achieves EcoVadis Gold
    FAMAR achieves EcoVadis Gold

    02 Apr 2025

    // PRESS RELEASE

    https://www.famar-group.com/new/famar-achieves-ecovadis-gold/

    PRESS RELEASE
    02 Apr 2025
    Share Share
    FAMAR Appoints New Executive to Leadership Team
    FAMAR Appoints New Executive to Leadership Team

    06 Jan 2025

    // PRESS RELEASE

    https://www.famar-group.com/new/famar-welcomes-a-new-member-to-its-executive-team-4/

    PRESS RELEASE
    06 Jan 2025
    Share Share
    CPHI Honors FAMAR with Gold Sustainability Certificate
    CPHI Honors FAMAR with Gold Sustainability Certificate

    12 Dec 2024

    // PRESS RELEASE

    https://www.famar-group.com/new/famar-s-stand-at-cphi-has-been-awarded-the-gold-better-stands-certificate-for-sustainability/

    PRESS RELEASE
    12 Dec 2024
    Share Share
    Bravo Sustainability Dialogue & Awards 2024
    Bravo Sustainability Dialogue & Awards 2024

    06 Dec 2024

    // PRESS RELEASE

    https://www.famar-group.com/new/bravo-sustainability-dialogue-amp-awards-2024/

    PRESS RELEASE
    06 Dec 2024
    Share Share
    FAMAR welcomes a new member to Executive Team
    FAMAR welcomes a new member to Executive Team

    31 Oct 2024

    // PRESS RELEASE

    https://www.famar-group.com/new/famar-welcomes-a-new-member-to-its-executive-team-3/

    PRESS RELEASE
    31 Oct 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Famar & D-Sight Partner for CMC Development & Clinical Batch Manufacturing

    Details:

    The collaboration aims to accelerate the development and production of clinical batches for D-Sight’s eye drops solution. It is being evaluated for the treatment of diabetic retinopathy.


    Lead Product(s): Undisclosed

    Therapeutic Area: Ophthalmology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Undisclosed

    Sponsor: D-Sight

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 13, 2024

    Famar

    01

    Famar

    Greece
    arrow
    CPhI North America
    Not Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Ophthalmology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : D-Sight

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Famar & D-Sight Partner for CMC Development & Clinical Batch Manufacturing

    Details : The collaboration aims to accelerate the development and production of clinical batches for D-Sight’s eye drops solution. It is being evaluated for the treatment of diabetic retinopathy.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    May 13, 2024

    Famar

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    FAMAR and Lavipharm Collaborate on Pharmaceutical Product Production

    Details:

    Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).


    Lead Product(s): Paracetamol,Caffeine

    Therapeutic Area: Immunology Brand Name: Lonarid N

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: LaviPharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration January 23, 2024

    Famar

    02

    Famar

    Greece
    arrow
    CPhI North America
    Not Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Lead Product(s) : Paracetamol,Caffeine

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : LaviPharm

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    FAMAR and Lavipharm Collaborate on Pharmaceutical Product Production

    Details : Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).

    Product Name : Lonarid N

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 23, 2024

    Famar

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Medicom Healthcare Ltd Announces the Signing of an Asset Purchase Agreement of BIMATOPROST 0.3 mg/mL, 3ml

    Details:

    Under this agreement, Medicom has acquired the ownership of the BIMATOPROST 0.3 mg/mL, 3ml dossier which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.


    Lead Product(s): Bimatoprost

    Therapeutic Area: Ophthalmology Brand Name: Zimed

    Study Phase: Approved FDFProduct Type: HPAPI

    Sponsor: Medicom Healthcare

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition October 02, 2021

    Famar

    03

    Famar

    Greece
    arrow
    CPhI North America
    Not Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Lead Product(s) : Bimatoprost

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Medicom Healthcare

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Medicom Healthcare Ltd Announces the Signing of an Asset Purchase Agreement of BIMATOPROST 0.3 mg/...

    Details : Under this agreement, Medicom has acquired the ownership of the BIMATOPROST 0.3 mg/mL, 3ml dossier which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.

    Product Name : Zimed

    Product Type : HPAPI

    Upfront Cash : Undisclosed

    October 02, 2021

    Famar

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod

    Details:

    Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.


    Lead Product(s): Laquinimod

    Therapeutic Area: Ophthalmology Brand Name: ABR-215062

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Active Biotech

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 02, 2021

    Famar

    04

    Famar

    Greece
    arrow
    CPhI North America
    Not Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

    Lead Product(s) : Laquinimod

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Active Biotech

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formu...

    Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.

    Product Name : ABR-215062

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 02, 2021

    Famar

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Packaging

    Discover their expertise for : Packaging

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Famar full-view
    Method validation & Transfer Activities
    full-view
    Oleo-Calcareous Liniment Lotion
    full-view
    Sterile Injectable Manufacturing
    full-view
    Phase I through III Liquid & Lyophilized Products
    full-view
    Multidose Eye Drops Manufacturing
    full-view
    Sprays & Atomizers
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search